Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

Bio2RDF uri

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02266433

Bio2RDF identifier

NCT02266433

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02266433

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02266433

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

780

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02266433 arm group aa82028248929e3ed00b449214d9dc19 [clinicaltrials_resource:NCT02266433/arm-group/aa82028248929e3ed00b449214d9dc19]

NCT02266433 arm group cbb2b9f4730ac8efc418a98d15c70a30 [clinicaltrials_resource:NCT02266433/arm-group/cbb2b9f4730ac8efc418a98d15c70a30]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

The primary objective o ...... ods, prospectively over time.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Dexamethasone Versus Ketorolac ...... and Upper Extremity Disorders

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:4dc31dd8afabff0e833a7e2d7a9e85fa]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:677a3dec7c4989a88e37fa6332228d5c]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:6f3b492e20a3910fc08e20b639f6a592]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:7f1d1d6e0c55e385ee6d4089649c0fa9]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:7fb91868c92dd228c45cd49d5ed7dacd]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:80181decd61883a92a9f83560f583826]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:a01dff2a05d67569757e2087c60bf843]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:a4d23c2ffb2f88497fc68a03b3dd6656]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:acb4b567a43500303b112368150c64fa]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:ae9a7ee21785bee813b0d486fa4a7f21]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Trigger Finger Treatment Group: Change in objective triggering based on Quinnell Grading System 0, 4, 8, 12 weeks, 6 months [clinicaltrials_resource:dd2706ef3d6d5124a175a3d994969386]

completion date [clinicaltrials_vocabulary:completion-date]

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Objectives: The primary ...... dexamethasone injection.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02266433 [clinicaltrials_resource:454867e5086cb612912198c99852b618]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Ketorolac [clinicaltrials_resource:c1a57fefd4e28edfec2e96c1538cb55a]

Dexamethasone [clinicaltrials_resource:cdc2f6e62399d72740843280e44880a9]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Dexamethasone acetate [clinicaltrials_resource:3aceb7ffcdb81af25927c64a2943afbf]

Dexamethasone [clinicaltrials_resource:81150ffec96d15927ad7a74665708ef9]

Ketorolac [clinicaltrials_resource:8b8220229152e2fdcc7687e625029f30]

BB 1101 [clinicaltrials_resource:9455fd6ce25c7014db1539bee52b8740]

Dexamethasone 21-phosphate [clinicaltrials_resource:9aea03ec731911e4ff43f23b2ed51296]

Ketorolac Tromethamine [clinicaltrials_resource:e24f542c0ee2817729577b0b9e29fa67]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

DeQuervains Tenosynovitis

http://www.w3.org/2001/XMLSchema#string

Dexamethasone

http://www.w3.org/2001/XMLSchema#string

Inflammatory Disease

http://www.w3.org/2001/XMLSchema#string

Ketorolac

http://www.w3.org/2001/XMLSchema#string

Lateral Epicondylitis

http://www.w3.org/2001/XMLSchema#string

Tennis Elbow

http://www.w3.org/2001/XMLSchema#string

Tenosynovitis

http://www.w3.org/2001/XMLSchema#string

Toradol

http://www.w3.org/2001/XMLSchema#string

Trigger Finger

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

New York University School of Medicine [clinicaltrials_resource:0ed54528c430d5cb50e83d287b1da509]

location [clinicaltrials_vocabulary:location]

New York University School of Medicine [clinicaltrials_resource:58acdcde01e131ed88997b3814e090e2]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02266433

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Double-blinded, Prospective, ...... and Upper Extremity Disorders

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

S12-00878

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Anthony Sapienza, MD [clinicaltrials_resource:5d37636c64cf9eb72b6d95eeba30d5ad]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Anthony Sapienza, MD [clinicaltrials_resource:114bc18f7c5415524e3e01e0818e72d9]

overall official [clinicaltrials_vocabulary:overall-official]

Anthony Sapienza, MD [clinicaltrials_resource:877de1ce2681d724cc37941e17f0d219]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:e30158d26f6957e092f5a16f1ea06cac]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

New York University School of Medicine [clinicaltrials_resource:0ed54528c430d5cb50e83d287b1da509]

start date [clinicaltrials_vocabulary:start-date]

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02266433 study design [clinicaltrials_resource:91402889c68e9c8bed1263b2f1d1309e]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02266433

verification date [clinicaltrials_vocabulary:verification-date]

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02266433

http://www.w3.org/2001/XMLSchema#string

title

Dexamethasone Versus Ketorolac ...... and Upper Extremity Disorders

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3